Abstract
Cancer vaccines are different in many ways from cytotoxic drugs. Consequently some of the paradigms for the early clinical development of cytotoxics are not applicable to the development of therapeutic vaccines. In contrast, many of the principles of phase III clinical trials are applicable to cancer vaccines. In this chapter we will describe design strategies for the efficient early clinical development of cancer vaccines.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Salgaller ML, Marincola F, Cormier, JN, Rosenberg, SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996; 56:4749–4757.
Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM. Enhancement of cellular immunity in melanoma patients immunized with a peptide form MART-1/Melan A. Cancer J Sci Am 1997; 3:37–44.
Casagrande JT, Pike MC, Smith PG. The power function of the “exact” test for comparing two binomial distributions. Appl Stat 1978; 27:176–180.
Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983; 1:710–719.
Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat Med 1984; 3:35–44.
Toni V, Simon R, Russek-Cohen E, Midthune D, Friedman M. Relationship of response and survival in advanced ovarian cancer patients treated with chemotherapy. J Natl Cancer Inst 1992; 84:407–414.
Fleming TR. One sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38:143.
Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1–10.
Ensign LG, Gehan EA, Kamen DS, Thall PF. An optimal three-stage design for phase II clinical trials. Stat Med 1994: 13:1727–1736.
Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, et al. Complete molecular remissions induced by patient specific vaccination plus granulocyte-monocyte colony stimulating factor against lymphoma. Nature Med 1999; 5:1171–1177.
Dixon DO, Simon R. Sample size considerations for studies comparing survival curves using historical controls. J Clin Epidemiol 1988; 41:1209–1213.
Rubinstein LV, Gail MH, Santner TJ. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J Chronic Dis 1981; 34:469–479.
Simon RM, Steinberg SM, Hamilton M, Hildesheim A, Khleif S, Kwak LW, et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001; 19:1848–1854.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc.
About this chapter
Cite this chapter
Simon, R. (2004). Clinical Trial Designs for Therapeutic Vaccine Studies. In: Morse, M.A., Clay, T.M., Lyerly, H.K. (eds) Handbook of Cancer Vaccines. Cancer Drug Discovery and Development. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-680-5_34
Download citation
DOI: https://doi.org/10.1007/978-1-59259-680-5_34
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-4684-9818-9
Online ISBN: 978-1-59259-680-5
eBook Packages: Springer Book Archive